1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Ilyang Pharmaceutical Co., Ltd.

Ilyang Pharmaceutical Co., Ltd.

7,100.00
KRW
+60.00
(+0.85%)
2014 Y
2015 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
147,732
211,798
186,285
261,615
269,811
300,036
324,573
343,329
242,511
247,773
266,669
268,678
272,422
277,956
Operating Margin (%)
3.2
2.95
8.33
8.6
9.06
5.57
10.02
9.93
6.26
5.75
6.14
3.58
1.82
-4.94
Depreciation Expense
5,158
10,668
9,339
11,387
11,701
12,019
10,090
12,664
11,227
11,767
11,971
9,824
8,344
8,467
Net Income, GAAP
3,963
-10,962
3,618
5,848
6,265
-4,893
9,985
10,880
14,032
19,385
-2,409
9,032
6,905
17,293
Effective Tax Rate (%)
29.62
- -
27.5
26.42
28.92
59.71
29.16
24.12
33.14
16.94
- -
14.84
46.21
23.04
Profit Margin (%)
2.68
-5.18
1.94
2.24
2.32
-1.63
3.08
3.17
5.79
7.82
-0.9
3.36
2.53
6.22
Working Capital
-16,591
-10,350
-31,267
-34,759
-40,571
-22,309
-8,922
-14,651
-31,580
-26,910
-15,604
-32,362
-23,410
-19,016
LT Debt
54,098
65,270
30,722
19,882
6,973
26,185
18,905
301
5,844
733
6,339
14,909
27,055
25,189
Total Equity
183,881
183,463
211,001
207,277
210,984
209,880
222,739
244,922
226,876
237,785
230,400
239,533
241,409
256,937
Return on Invested Capital (%)
0.99
- -
3.05
4.56
4.84
1.9
6.62
7.49
3.05
3.78
- -
2.56
0.76
-2.98
Return on Capital (%)
2.28
- -
0.59
1.03
0.85
-3.12
0.96
0.72
4.33
6.51
- -
3.47
2.32
5.23
Return on Common Equity (%)
2.18
-6.17
1.98
3.06
3.3
-2.59
5.23
5.41
6.55
8.5
-1.05
3.92
2.93
7.1

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
99,739
86,579
78,481
LT Borrowings
26,667
25,833
25,000
LT Finance Leases
389
234
189
Preferred Equity and Hybrid Capital
1,113
1,113
1,113
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
147,762
153,076
135,818
Cash, Cash Equivalents & STI
29,627
39,658
17,738
Accounts Receivable, Net
44,972
40,242
37,787
Inventories
64,243
62,256
67,514
Total Current Liabilities
171,172
163,989
154,833
Payables & Accruals
- -
- -
- -
ST Debt
99,739
86,579
78,481
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.47%
-0.19%
0.78%
Free Cash Flow
727.71%
-86.54%
-104.58%
Net Income, GAAP
-94.83%
-108.76%
-23.55%
Sales/Revenue/Turnover
5.13%
-3.48%
1.39%
Total Cash Common Dividend
22.31%
-2.42%
-3.15%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
58,724
58,469
69,090
8,525
268,678
2025
61,983
62,701
68,827
78,912
272,422
2026
65,074
65,144
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yoo-Seok Chung
Full Time Employees
665
Sector
Health technology
Industry
Pharmaceuticals: major
Address
110, Hagal-ro Yongin-si GY South Korea 17096
IPO Date
Aug 28, 1974
Website
ilyang.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Ilyang Pharmaceutical Co., Ltd. (007570.KS) develops, manufactures and markets a broad portfolio of branded pharmaceuticals targeting oncology, circulatory disorders, endocrine and metabolic conditions, acid-related gastrointestinal diseases, female hormones, urinary tract issues, ophthalmology, liver diseases, anti-inflammatory analgesics, digestive disorders, dermatology, respiratory conditions, neurology and nutrient infusions; key products include the tyrosine kinase inhibitor Supect (radotinib) for chronic myeloid leukemia, the proton pump inhibitor Noltec (ilaprazole) for peptic ulcers and reflux esophagitis, IL-YANG flu vaccine, antibiotics, antifungal agents, vaccines, health drinks such as Wonbi-D, cosmetics, beverages, supplements and pharmaceutical raw materials like aluminum hydroxide gel, magnesium hydroxide, hydrotalcite and almagate. The company, founded in 1946 and headquartered at 110 Hagal-ro, Giheung-gu, Yongin, South Korea, primarily serves the domestic Korean market with exports to select international regions including Russia, Armenia and Belarus through licensing agreements, and operates advanced R&D facilities focused on new chemical entities, vaccines and biologics. Recent developments encompass ongoing clinical advancements for Noltec including a phase I pharmacokinetics trial completed in August 2024 and a planned phase III trial for peptic ulcer prevention starting August 2024, sustained commercialization of Supect with approvals in China as of September 2022 and active R&D pipeline expansions in acid-related diseases and chronic myelogenous leukemia treatments, alongside a 14.3 billion won order win and equity buyback tranche update in 2025.